Direxion Daily Pharmaceutical & Medical Bull 3X ETF(PILL · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$13.62
- 52-Week Range
- $5.06 – $14.25
- YTD
- +15.82%
- IV Rank (30D)
- 11.86
- Straddle Price
- $2.23
- P/C Vol Ratio
- 0.09
Info
Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) ETF
- Exchange
- ARCX
- Inception
- 2017-11-15
- Has Options
- Yes
ETF Profile
holdings as of 2026-06-12
Holdings
64
AUM
$45.5M
Provider
Direxion
Inception
2017-11-15
Exchange
ARCX
Data As Of
2026-06-12
Expense Ratio
—
Dividend Yield
0.58%
Distribution
Quarterly
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-03-24 | 2026-03-31 | $0.0109 | CD |
| 2025-12-23 | 2025-12-31 | $0.0326 | CD |
| 2025-09-23 | 2025-09-30 | $0.0098 | CD |
| 2025-06-24 | 2025-07-01 | $0.0245 | CD |
| 2025-03-25 | 2025-04-01 | $0.0183 | CD |
| 2024-12-23 | 2024-12-31 | $0.0131 | CD |
Asset Allocation
Top Holdings
top 50 of 64 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | S&P PHARMACEUTICALS SELECT INDEX SWAP | 115.62% | Derivative | — |
| — | S&P PHARMACEUTICALS SELECT INDEX SWAP | 61.59% | Derivative | — |
| — | S&P PHARMACEUTICALS SELECT INDEX SWAP | 57.81% | Derivative | — |
| — | GOLDMAN FINL SQ TRSRY INST 506 | 15.61% | Derivative | — |
| — | DREYFUS GOVT CASH MAN INS | 8.95% | Derivative | — |
| CORT | CORCEPT THERAPEUTICS INC | 2.83% | Equity (US) | — |
| OGN | ORGANON & CO | 2.41% | Equity (US) | — |
| — | GOLDMAN SACHS FIN GOV 465 INSTITUT | 2.23% | Derivative | — |
| LQDA | LIQUIDIA CORP | 2.13% | Equity (US) | — |
| AXSM | AXSOME THERAPEUTICS INC | 1.83% | Equity (US) | — |
| ELVN | ENLIVEN THERAPEUTICS INC | 1.51% | Equity (US) | — |
| DFTX | Definium Therapeutics, Inc | 1.49% | Equity (US) | — |
| AMRX | AMNEAL PHARMACEUTICALS INC | 1.48% | Equity (US) | — |
| JAZZ | JAZZ PHARMACEUTICALS PLC | 1.46% | Equity (US) | — |
| MBX | MBX BIOSCIENCES INC | 1.45% | Equity (US) | — |
| HRMY | HARMONY BIOSCIENCES HOLDINGS | 1.40% | Equity (US) | — |
| RPRX | ROYALTY PHARMA PLC- CL A | 1.36% | Equity (US) | — |
| ESPR | ESPERION THERAPEUTICS INC | 1.35% | Equity (US) | — |
| VTRS | VIATRIS INC | 1.34% | Equity (US) | — |
| INDV | INDIVIOR PHARMACEUTICALS INC | 1.33% | Equity (US) | — |
| LLY | ELI LILLY & CO | 1.32% | Equity (US) | — |
| LGND | LIGAND PHARMACEUTICALS | 1.32% | Equity (US) | — |
| XERS | XERIS BIOPHARMA HOLDINGS INC | 1.32% | Equity (US) | — |
| TRVI | TREVI THERAPEUTICS INC | 1.29% | Equity (US) | — |
| PRGO | PERRIGO CO PLC | 1.28% | Equity (US) | — |
| EWTX | EDGEWISE THERAPEUTICS INC | 1.26% | Equity (US) | — |
| ANIP | ANI PHARMACEUTICALS INC | 1.23% | Equity (US) | — |
| MRK | MERCK & CO. INC. | 1.19% | Equity (US) | — |
| NUVB | NUVATION BIO INC | 1.19% | Equity (US) | — |
| ELAN | ELANCO ANIMAL HEALTH INC | 1.18% | Equity (US) | — |
| PCRX | PACIRA BIOSCIENCES INC | 1.18% | Equity (US) | — |
| HROW | HARROW INC | 1.17% | Equity (US) | — |
| INVA | INNOVIVA INC | 1.15% | Equity (US) | — |
| JNJ | JOHNSON & JOHNSON | 1.13% | Equity (US) | — |
| COLL | COLLEGIUM PHARMACEUTICAL INC | 1.11% | Equity (US) | — |
| PFE | PFIZER INC | 1.10% | Equity (US) | — |
| BMY | BRISTOL-MYERS SQUIBB CO | 1.09% | Equity (US) | — |
| AMLX | AMYLYX PHARMACEUTICALS INC | 1.07% | Equity (US) | — |
| OCUL | OCULAR THERAPEUTIX INC | 1.05% | Equity (US) | — |
| CRNX | CRINETICS PHARMACEUTICALS IN | 1.04% | Equity (US) | — |
| TARS | TARSUS PHARMACEUTICALS INC | 1.03% | Equity (US) | — |
| SUPN | SUPERNUS PHARMACEUTICALS INC | 0.98% | Equity (US) | — |
| OMER | OMEROS CORP | 0.98% | Equity (US) | — |
| CRMD | CORMEDIX INC | 0.97% | Equity (US) | — |
| EYPT | EYEPOINT INC | 0.96% | Equity (US) | — |
| NKTR | NEKTAR THERAPEUTICS | 0.93% | Equity (US) | — |
| RAPP | RAPPORT THERAPEUTICS INC | 0.92% | Equity (US) | — |
| ALMS | ALUMIS INC | 0.91% | Equity (US) | — |
| AMPH | AMPHASTAR PHARMACEUTICALS IN | 0.91% | Equity (US) | — |
| TBPH | THERAVANCE BIOPHARMA INC | 0.86% | Equity (US) | — |
Geographic Breakdown
Fund Holdings
Direxion Daily Pharmaceutical & Medical Bull 3X Shares ·
NPORT-P period 2026-10-31
(filed 2026-04-01)
Net assets:
$18M
· 65 total positions
· equity 75.63%
· non-equity 28.72%
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | Definium Therapeutics, Inc | Definium Therapeutics Inc. | 1.95% | $349365 |
| 2 | LIQUIDIA CORP | Liquidia Corporation | 1.85% | $332422 |
| 3 | MBX BIOSCIENCES INC | MBX Biosciences, Inc. | 1.83% | $327670 |
| 4 | Axsome Therapeutics Incorporation COM USD0.0001 | Axsome Therapeutics Inc. | 1.76% | $316357 |
| 5 | Organon & Co COMMON STOCK | Organon & Co | 1.70% | $304758 |
| 6 | EDGEWISE THERAPEUTICS INC | Edgewise Therapeutics Inc. | 1.69% | $303879 |
| 7 | Elanco Animal Health Inc COM NPV | Elanco Animal Health Inc | 1.62% | $289682 |
| 8 | Merck & Co., Inc COM USD0.50 | Merck & Co., Inc | 1.61% | $289348 |
| 9 | Viatris Inc COM | Viatris Inc | 1.61% | $289145 |
| 10 | AMNEAL PHARMACEUTICALS INC | Amneal Pharmaceuticals Inc | 1.60% | $287075 |
| 11 | Johnson & Johnson COM USD1.00 | Johnson & Johnson | 1.57% | $281790 |
| 12 | Royalty Pharma PLC COM USD0.0001 CLASS A | Royalty Pharma PLC | 1.56% | $279256 |
| 13 | AMYLYX PHARMACEUTICALS INC | Amylyx Pharmaceuticals Inc | 1.54% | $276783 |
| 14 | Bristol-Myers Squibb Company COM USD0.10 | Bristol-Myers Squibb Company | 1.54% | $275525 |
| 15 | XERIS BIOPHARMA HOLDINGS INC | Xeris Biopharma Holdings Inc | 1.52% | $271739 |
| 16 | Zoetis Inc. COM USD0.01 CL 'A' | Zoetis Inc. | 1.51% | $270984 |
| 17 | Perrigo Company PLC COM EUR0.001 | Perrigo Company PLC | 1.50% | $269336 |
| 18 | Prestige Consumer Healthcare Inc COM USD0.01 | Prestige Consumer Healthcare Inc | 1.50% | $269162 |
| 19 | Ligand Pharmaceuticals Incorporated 'B'COM USD0.001 | Ligand Pharmaceuticals Incorporated | 1.49% | $267403 |
| 20 | Supernus Pharmaceuticals, Inc COM USD0.001 | Supernus Pharmaceuticals, Inc | 1.49% | $267384 |
| 21 | Eli Lilly & Co. COM NPV | Eli Lilly & Co. | 1.49% | $266548 |
| 22 | CRINETICS PHARMACEUTICALS IN | Crinetics Pharmaceuticals Inc. | 1.48% | $266280 |
| 23 | Pfizer Inc. COM USD0.05 | Pfizer Inc. | 1.47% | $262787 |
| 24 | Arvinas Inc COM USD0.001 | Arvinas Inc | 1.44% | $258823 |
| 25 | AVADEL PHARMACEUTICALS | Avadel Pharmaceuticals PLC | 1.43% | $257048 |
Showing top 25 of 59 equity holdings.
Non-equity holdings
— 6 positions,
28.72% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 32.92% | $5.9M | 3 |
| Derivative (equity) | -4.19% | $-752256 | 3 |
Daily issuer data also available
(2026-06-13)
via ETF Constituents
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +3.56% | 6 |
| Feb | -0.28% | 6 |
| Mar | -7.53% | 6 |
| Apr | -7.50% | 6 |
| May | -2.28% | 6 |
| Jun | +2.43% | 6 |
| Jul | +11.78% | 5 |
| Aug | -1.99% | 5 |
| Sep | -10.80% | 5 |
| Oct | -1.31% | 5 |
| Nov | +3.15% | 5 |
| Dec | +2.08% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $12.00
SMA 50: $12.20
SMA 200: $10.81
Current: $13.53
EMA 12: $12.36
EMA 26: $12.22
MACD: 0.1335 | Signal: 0.1612
BEARISH
ADX (14): 14.74
RANGE
+DI: 36.77
−DI: 18.76
Momentum Oscillators
RSI (14): 61.59
NEUTRAL
Stoch %K: 83.41
Stoch %D: 72.85
Williams %R: -9.87
Volume & Volatility
BB Upper: $13.38
BB Lower: $10.62
OVERBOUGHT
OBV: 2,840,107
Vol SMA 20: 68,593
Vol ROC: 157.15%
ATR: $0.76
True Range: $0.69
HV 20: 80.4%
HV 30: 72.4%
HV 60: 73.3%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:20.509000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 11.86
- IV Rank (7D)
- 40.74
- Avg IV
- 111.8%
- Straddle (30D)
- $2.23
- Straddle (7D)
- $1.25
- P/C Volume
- 0.09
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 2.63
- Correlation (SPY)
- 51.8%
- R²
- 0.27
- Ann. Volatility
- 62.8%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Beta & Alpha Over Time
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|